Abstract:Mannooligosaccharides (MOS) were purified from the thermally hydrolyzed mannan in spent coffee grounds, with the aim of achieving the full utilization of natural unused food material. The effects of MOS on fecal microflora and the defecating conditions in eight healthy volunteers were investigated. The subjects were administered MOS at 1.0 g/day and 3.0 g/day for 2 weeks. A 2 week interval was observed between the two dose intake periods. The content of Bifidobacterium significantly increased during the two pe… Show more
“…Immunological effects of nondigestible oligosaccharides, such as fructooligosaccharides (FOS), 2,3) galactooligosaccharides, 4) and raffinose, 5) have been demonstrated. Recently, our studies have revealed that mannooligosaccharides (MOS) from coffee mannan improves the intestinal environment 6,7) by increasing Bifidobacterium. 8,9) MOS are mannosebased oligosaccharides with β-1, 4 linkages.…”
The effects of the dietary mannooligosaccharides (MOS) from coffee mannan on the anti-allergic functions were examined using C3H/HeN mice. The mice were given water and a dietary treatment containing 2.5% MOS ad libitum. The mice were sensitized subcutaneously with ovalbumin on the 7th, 21st, and 35th days and then sensitized intraperitoneally on the 49th day of the study. Serum samples, Peyer's patches and peritoneal exudate fluids were collected on the 50th day. In the non-ovalbumin sensitized groups, phosphate-buffered saline (PBS) was injected instead of ovalbumin. The number of peritoneal acidophils in the MOS diet-fed mice, was significantly lower than that in the control diet-fed ones. MOS treatment significantly reduced interleukin-10 production and tended to suppress ovalbumin-specific IgE in serum. However, it did not change interleukin-2 and interferon-γ production. These results suggest that dietary MOS may have an anti-allergic effect, caused by activation of cellular immunity.
“…Immunological effects of nondigestible oligosaccharides, such as fructooligosaccharides (FOS), 2,3) galactooligosaccharides, 4) and raffinose, 5) have been demonstrated. Recently, our studies have revealed that mannooligosaccharides (MOS) from coffee mannan improves the intestinal environment 6,7) by increasing Bifidobacterium. 8,9) MOS are mannosebased oligosaccharides with β-1, 4 linkages.…”
The effects of the dietary mannooligosaccharides (MOS) from coffee mannan on the anti-allergic functions were examined using C3H/HeN mice. The mice were given water and a dietary treatment containing 2.5% MOS ad libitum. The mice were sensitized subcutaneously with ovalbumin on the 7th, 21st, and 35th days and then sensitized intraperitoneally on the 49th day of the study. Serum samples, Peyer's patches and peritoneal exudate fluids were collected on the 50th day. In the non-ovalbumin sensitized groups, phosphate-buffered saline (PBS) was injected instead of ovalbumin. The number of peritoneal acidophils in the MOS diet-fed mice, was significantly lower than that in the control diet-fed ones. MOS treatment significantly reduced interleukin-10 production and tended to suppress ovalbumin-specific IgE in serum. However, it did not change interleukin-2 and interferon-γ production. These results suggest that dietary MOS may have an anti-allergic effect, caused by activation of cellular immunity.
“…1) Previous studies have revealed that MOS can promote the growth of bifidobacteria in the intestines and improve the fecal characteristic on human subjects. 2) We have recently been investigating alternative physiological functions of MOS from various perspectives. Asano et al reported the result of their long-term clinical study on human subjects: A daily intake of a 300 ml drink containing MOS (1 or 2 g/100 ml) lowered the level of abdominal and subcutaneous fat when administered everyday for twelve weeks.…”
Mice were fed either a high fat diet or a high fat diet containing 1% mannooligosaccharides (MOS) for twelve weeks. The effects of MOS on fat accumulation and excretion were examined. After twelve weeks, the percentage weight of the fat and hepatic triglyceride level were significantly lower in the MOS group than that of the control group (p < 0.05 and p < 0.01 respectively). Furthermore, the serum triglyceride level had a decreasing tendency in the MOS group (p = 0.058). On the other hand, the fecal triglyceride level as well as the amount of fat excreted significantly increased in the MOS group (p < 0.05). This study showed that the administration of MOS lessened the fat accumulation in the parametrial adipose tissue and the liver while at the same time increased the amount of fat being excreted. These results indicate that MOS may prevent the fat storage through inhibiting the intestinal absorption of dietary fat in a high fat diet.
“…[1][2][3] Further investigations have been undertaken to explore the potential functionality of MOS. The liquid coffee beverage containing 3.0 g/day of MOS, assisted in reducing the areas of subcutaneous and visceral fat in somewhat overweight adults when consumed for 12 weeks.…”
Liquid coffee and milk based liquid coffee, both containing 1.0 g of mannooligosaccharides (MOS) from coffee mannan, were administered to two groups of six subjects each. The subjects consumed one or the other of the beverage everyday for two weeks. The level of fat in their excrement was subsequently analyzed. In both liquid coffee (p < 0.05, respectively) and milk based liquid coffee (p < 0.05, respectively), the concentration of the beverage containing MOS intake showed a significant decrease in comparison with the placebo and interval or those who did not drink any coffee. The result suggests that the intake of MOS can increase the level of fat excreted from the body irrespective.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.